Use of a Polylactic Acid Membrane for Wound Care After Severe Herpes Zoster (Shingles): A Case Report.
- 1Wound Clinic of the Regional High-Specialty Hospital "Ignacio Morones Prieto", San Luis Potosí 78220, SLP, Mexico.
- 2Division of Experimental Surgery, Faculty of Medicine, McGill University, Montreal, QC H3G 1A4, Canada.
Abstract
Background and Clinical Significance: Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus and disproportionately affects older adults. Antiviral therapy and systemic analgesia are well established, but local wound care of the eroded skin remains largely empirical: no dressing has been validated in controlled trials for this indication, and denuded HZ lesions are frequently mismanaged with dry gauze that adheres to the wound bed and aggravates pain. Case Presentation: An 85-year-old man with no known chronic disease presented with a one-week history of thoracic HZ unresponsive to outpatient antiviral therapy, requiring admission for uncontrolled pain (9/10 on the Numeric Rating Scale, NRS), vomiting, asthenia, and hyporexia. Examination revealed confluent, superficial-partial-thickness erosions across the T6-T8 dermatomes (12.5 × 24 cm). After a negative wound culture, a single polylactic-acid-based membrane (Suprathel®250) was applied over the entire denuded area. Pain decreased from 9/10 to 2/10 on the NRS within seven days and complete re-epithelialization was observed by day 12, under concurrent antiviral and systemic analgesic therapy and the patient resumed independent daily activities by the third week without scarring. Conclusions: In this single uncontrolled case, pain reduction and wound closure followed one application of a polylactic acid membrane to an extensive HZ lesion. Because antiviral and analgesic therapy were given concurrently and HZ improves spontaneously over time, no causal or comparative inference is possible; the observation is hypothesis-generating and supports further controlled investigation. Suprathel® is CE-marked and FDA-cleared for burn and wound care, so its use for HZ erosions extends an established burn indication.
Related
- Herpes Zoster in an Immunocompetent Child Following an Influenza-Like Illness
- Herpes zoster and major vascular events in a general population without prior cardiovascular event from Shizuoka Kokuho database
- Association of platelet-rich plasma combined with dorsal root ganglion-targeted pulsed radiofrequency with outcomes in subacute thoracic herpes zoster neuralgia: a retrospective cohort study
- Development of mRNA vaccines against herpes zoster.
- The effect of herpes zoster vaccines on incident dementia in England: Protocol for an OpenSAFELY regression discontinuity study
BibTeX
@article{lozagonzalez2026polylactic,
title = {{Use of a Polylactic Acid Membrane for Wound Care After Severe Herpes Zoster (Shingles): A Case Report.}},
author = {Víctor Manuel Loza-González and Patricia Aurea Cervantes-Báez and Andrea Paola Saucedo-Quintero and José Luis Ramírez-GarcíaLuna and Mario Aurelio Martínez-Jiménez},
journal = {Reports (MDPI)},
year = {2026},
month = oct,
doi = {10.3390/reports9040362},
url = {https://europepmc.org/article/MED/42924814},
note = {CC BY},
}
RIS
TY - JOUR
TI - Use of a Polylactic Acid Membrane for Wound Care After Severe Herpes Zoster (Shingles): A Case Report.
AU - Víctor Manuel Loza-González
AU - Patricia Aurea Cervantes-Báez
AU - Andrea Paola Saucedo-Quintero
AU - José Luis Ramírez-GarcíaLuna
AU - Mario Aurelio Martínez-Jiménez
PY - 2026
DA - 2026/10/19
JO - Reports (MDPI)
DO - 10.3390/reports9040362
UR - https://europepmc.org/article/MED/42924814
AB - Background and Clinical Significance: Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus and disproportionately affects older adults. Antiviral therapy and systemic analgesia are well established, but local wound care of the eroded skin remains largely empirical: no dressing has been validated in controlled trials for this indication, and denuded HZ lesions are frequently mismanaged with dry gauze that adheres to the wound bed and aggravates pain. Case Presentation: An 85-year-old man with no known chronic disease presented with a one-week history of thoracic HZ unresponsive to outpatient antiviral therapy, requiring admission for uncontrolled pain (9/10 on the Numeric Rating Scale, NRS), vomiting, asthenia, and hyporexia. Examination revealed confluent, superficial-partial-thickness erosions across the T6-T8 dermatomes (12.5 × 24 cm). After a negative wound culture, a single polylactic-acid-based membrane (Suprathel®250) was applied over the entire denuded area. Pain decreased from 9/10 to 2/10 on the NRS within seven days and complete re-epithelialization was observed by day 12, under concurrent antiviral and systemic analgesic therapy and the patient resumed independent daily activities by the third week without scarring. Conclusions: In this single uncontrolled case, pain reduction and wound closure followed one application of a polylactic acid membrane to an extensive HZ lesion. Because antiviral and analgesic therapy were given concurrently and HZ improves spontaneously over time, no causal or comparative inference is possible; the observation is hypothesis-generating and supports further controlled investigation. Suprathel® is CE-marked and FDA-cleared for burn and wound care, so its use for HZ erosions extends an established burn indication.
SN - 2571-841X
ER -